European Journal of Cancer
Volume 41, Issue 6 , Pages 834-845 , April 2005

Changing demography of prostate cancer in Asia

Received 19 August 2004 ,Accepted 2 December 2004.

References 

  1. Ferlay J, Bray F, Pisani P, et al. GLOBOSCAN 2000: cancer incidence, mortality and prevalence worldwide. Lyon: International Agency for Research on Cancer; 2001;
  2. Potosky AL, Miller BA, Albertsen PC, et al. The role of increasing detection in the rising incidence of prostate cancer. JAMA. 1995;273:548–552
  3. Majeed FA, Burgess NA. Trends in death rates and registration rates for prostate cancer in England and Wales. BJU. 1994;73:377–381
  4. Chirpaz E, Colonna M, Menegoz F, et al. Incidence and mortality trends for prostate cancer in 5 French areas from 1982 to 1996. Int J Cancer. 2002;97(3):372–376
  5. Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85:60–67
  6. In:  Muir C,  Waterhouse J,  Mack T, et al. editor. Cancer incidence in five continents, vol. V. IARC Scientific Publications, 88. Lyon: International Agency for Research in Cancer; 1987;
  7. In:  Parkin DM,  Muir CS,  Whelan SL, et al. editor. Cancer incidence in five continents, vol. VI. IARC Scientific Publications, 120. Lyon: International Agency for Research in Cancer; 1992;
  8. In:  Parkin DM,  Whelan SL,  Ferlay J, et al. editor. Cancer incidence in five continents, vol. VII. IARC Scientific Publications, 143. Lyon: International Agency for Research in Cancer; 1997;
  9. In:  Parkin DM,  Whelan SL,  Ferlay J, et al. editor. Cancer incidence in five continents, vol. VIII. IARC Scientific Publications, 155. Lyon: International Agency for Research in Cancer; 2002;
  10. World Health Organisation. Mortality Data Bank, June 2004. Available from: http://www-depdb.iarc.fr/who/menu.htm
  11. Shibata A, Ma J, Whittemore AS. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst. 1998;90:1230–1231
  12. Tan HH, Gan E, Rekhraj I, et al. Use of prostate-specific antigen and transrectal ultrasound in the diagnosis of prostate cancer – a local experience. Ann Acad Med Singapore. 1995;24:550–556
  13. Wong BTH, Que MBW, Szeto PS, et al. Establishing a ‘reference range’ of serum prostate-specific antigen for Asians. Asian J Surg. 1999;22:240–244
  14. Ng LG, Yip S, Tan PH, et al. Improved detection rate of prostate cancer using the 10-core biopsy strategy in Singapore. Asian J Surg. 2002;25(3):238–243
  15. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25(2):276–308
  16. Edwards A, Hammond HA, Jin L, et al. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics. 1992;12:241–253
  17. Irvine RA, Yu MC, Ross RK, et al. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res. 1995;55(9):1937–1940
  18. Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci. 1997;94:3320–3323
  19. Sartor O, Zheng Q, Eastham JA. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer. Urology. 1999;53(2):378–380
  20. Hsing AW, Gao YT, Wu G, et al. Polymorphic CAG and GGC repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case control study in China. Cancer Res. 2000;60(18):5111–5116
  21. Liu JH, Li HW, Tong M, et al. Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer. Zhonghua Yi Xue Za Zhi. 2004;84(5):364–368
  22. Jin B, Beilin J, Zajac J, et al. Androgen receptor gene polymorphism and prostate zonal volumes in Australian and Chinese men. J Androl. 2000;21(1):91–98
  23. Platz EA, Rimm EB, Willett WC, et al. Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals. J Natl Cancer Inst. 2000;92(24):2009–2017
  24. Habuchi T, Suzuki T, Sasaki R, et al. Association of vitamin D receptor gene polymorphism with prostate cancer and benign prostatic hyperplasia in a Japanese population. Cancer Res. 2000;60(2):305–308
  25. Huang SP, Chou YH, Wayne Chang WS, et al. Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population. Cancer Lett. 2004;207(1):69–77
  26. Ntais C, Polycarpou A, Ioannidis JP. Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1395–1402
  27. Tayeb MT, Clark C, Haites NE, et al. CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia. Br J Cancer. 2003;88(6):928–932
  28. Suzuki K, Matsui H, Ohtake N, et al. Vitamin D receptor gene polymorphism in familial prostate cancer in a Japanese population. Int J Urol. 2003;10(5):261–266
  29. Cheteri MB, Stanford JL, Friedrichsen DM, et al. Vitamin D receptor gene polymorphisms and prostate cancer risk. Prostate. 2004;59(4):409–418
  30. Yang Y, Wang S, Ye Z, et al. Association of single nucleotide polymorphism of vitamin D receptor gene start codon and the susceptibility to prostate cancer in the Han nationality in Hubei area. Zhonghua Nan Ke Xue. 2004;10(6):411–414
  31. Liu JH, Li HW, Wang JQ, et al. Vitamin D receptor gene BsmI polymorphism and the susceptibility to prostate cancer in northern Chinese Han population. Zhonghua Nan Ke Xue. 2003;9(6):413–416
  32. Chokkalingam AP, McGlynn KA, Gao YT, et al. Vitamin D receptor gene polymorphisms, insulin-like growth factors, and prostate cancer risk: a population-based case-control study in China. Cancer Res. 2001;61(11):4333–4336
  33. Lunn RM, Bell DA, Mohler JL, et al. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis. 1999;20(9):1727–1731
  34. Gsur A, Bernhofer G, Hinteregger S, et al. A polymorphism in the CYP17 gene is associated with prostate cancer risk. Int J Cancer. 2000;87(3):434–437
  35. Haiman CA, Stampfer MJ, Giovannucci E, et al. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2001;10(7):743–748
  36. Yamada Y, Watanabe M, Murata M, et al. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population. Int J Cancer. 2001;92(5):683–686
  37. Habuchi T, Liqing Z, Suzuki T, et al. Increased risk of prostate cancer and benign prostatic hyperplasia associated with a CYP17 gene polymorphism with a gene dosage effect. Cancer Res. 2000;60(20):5710–5713
  38. Madigan MP, Gao YT, Deng J, et al. CYP17 polymorphisms in relation to risks of prostate cancer and benign prostatic hyperplasia: a population-based study in China. Int J Cancer. 2003;107(2):271–275
  39. Lin CC, Wu HC, Chen WC, et al. CYP17 gene promoter allelic variant is not associated with prostate cancer. Urol Oncol. 2003;21(4):262–265
  40. Nam RK, Toi A, Vesprini D, et al. V89L polymorphism of type-2, 5-alpha reductase enzyme gene predicts prostate cancer presence and progression. Urology. 2001;57(1):199–204
  41. Hsing AW, Chen C, Chokkalingam AP, et al. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2001;10(10):1077–1082
  42. Febbo PG, Kantoff PW, Platz EA, et al. The V89L polymorphism in the 5alpha-reductase type 2 gene and risk of prostate cancer. Cancer Res. 1999;59(23):5878–5881
  43. Coffey DS. Physiological control of prostate growth. An overview. In: Prostate cancer. UICC technical report series, vol. 48. Geneva: International Union Against Cancer; 1999
  44. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate, 1941. J Urol. 2002;168(1):9–12
  45. Ross R, Bernstein L, Judd H, et al. Serum testosterone levels in healthy young black and white men. J Natl Cancer Inst. 1986;76(1):45–48
  46. Ross RK, Bernstein L, Lobo RA, et al. 5-alpha-Reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992;339(8798):887–889
  47. Wu AH, Whittemore AS, Kolonel LN, et al. Serum androgens and sex hormone-binding globulins in relation to lifestyle factors in older African–American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomarkers Prev. 1995;4(7):735–741
  48. Gann PH, Hennekens CH, Ma J, et al. Prospective study of sex hormone levels and risks of prostate cancer. J Natl Cancer Inst. 1996;88(16):1118–1126
  49. Demark-Wahnefried W, Lesko SM, Conaway MR, et al. Serum androgens: associations with prostate cancer risk and hair patterning. J Androl. 1997;18(5):495–500
  50. Shaneyfelt T, Husein R, Bubley G, et al. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol. 2000;18(4):847–853
  51. Vatten LJ, Ursin G, Ross RK, et al. Androgens in serum and the risk of prostate cancer: a nested control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers Prev. 1997;6:967–969
  52. Heikkila R, Aho K, Heliovaara M, et al. Serum testosterone and sex hormone-binding globulin concentrations and the risk of prostate carcinoma: a longitudinal study. Cancer. 1999;86(2):312–315
  53. Mohr BA, Feldman HA, Kalish LA, et al. Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts male aging study. Urology. 2001;57(5):930–935
  54. Chen C, Weiss NS, Stanczyk FZ, et al. Endogenous sex hormones and prostate cancer risk: a case-control study nested within the carotene and retinol efficacy trial. Cancer Epidemiol Biomarkers Prev. 2003;12(12):1410–1416
  55. Dorgan JF, Albanes D, Virtamo J, et al. Relationships of serum androgens and estrogens to prostate cancer risk: results from a prospective study in Finland. Cancer Epidemiol Biomarkers Prev. 1998;7(12):1069–1074
  56. Cohen P, Peehl DM, Lamson G, et al. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab. 1991;73:401–407
  57. Iwamura M, Sluss PM, Casamento JB, et al. Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate. 1993;22:243–252
  58. Pollak M, Beamer W, Zhang JC. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev. 1999;17:383–390
  59. Prager D, Li HL, Asa S, et al. Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc Natl Acad Sci USA. 1994;91:2181–2185
  60. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science. 1998;279:5350–5636
  61. Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor-I and prostate cancer risk: a population-based case-control study. J Natl Cancer Inst. 1998;90(12):911–915
  62. Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study. J Natl Cancer Inst. 2000;92(23):1910–1917
  63. Djavan B, Bursa B, Seitz C, et al. Insulin-like growth factor-I, IGF-I density, and IGF-I/PSA ratio for prostate cancer detection. Urology. 1999;54(4):603–606
  64. Li L, Yu H, Schumacher F, et al. Relation of serum insulin-like growth factor-I and IGF binding protein-3 to risk of prostate cancer (United States). Cancer Causes Control. 2003;14(8):721–726
  65. Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor-I, IGF-binding protein-3 and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346–1353
  66. Woodson K, Tangrea JA, Pollak M, et al. Serum insulin-like growth factor-I: tumour marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res. 2003;63(14):3991–3994
  67. Aksoy Y, Aksoy H, Bakan E, et al. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. Urol Int. 2004;72(1):62–65
  68. Chokkalingam AP, Pollak M, Fillmore CM, et al. Insulin-like growth factors and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 2001;10(5):421–427
  69. Signorello LB, Adami H. Prostate cancer. In:  Adami H,  Hunter D,  Trichopoulos D editor. Textbook of cancer epidemiology. New York: Oxford University Press; 2002;p. 400–419
  70. Dunn JE. Cancer epidemiology in populations of the United States – with emphasis on Hawaii and California – and Japan. Cancer Res. 1975;35(11 Pt. 2):3240–3245
  71. Santner SJ, Albertson B, Zhang GY, et al. Comparative rates of androgen production and metabolism in Caucasian and Chinese subjects. J Clin Endocrinol Metab. 1998;83(6):2104–2109
  72. Cook LS, Goldoft M, Schwartz SM, et al. Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. J Urol. 1999;161(1):151–155
  73. Trachtenberg J, Hicks LL, Walsh PC. Androgen- and estrogen-receptor content in spontaneous and experimentally induced canine prostatic hyperplasia. J Clin Invest. 1980;65(5):1051–1059
  74. Andersson SO, Wolk A, Bergstrom R, et al. Body size and prostate cancer: a 20-year follow-up study among 135006 Swedish construction workers. J Natl Cancer Inst. 1997;89(5):385–389
  75. Rodriguez C, Patel AV, Calle EE, et al. Body mass index, height, and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev. 2001;10(4):345–353
  76. Hsing AW, Deng J, Sesterhenn IA, et al. Body size and prostate cancer: a population-based case-control study in China. Cancer Epidemiol Biomarkers Prev. 2000;9(12):1335–1341
  77. Giovannucci E, Rimm EB, Liu Y, et al. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst. 2003;95(16):1240–1244
  78. Hubbard JS, Rohrmann S, Landis PK, et al. Association of prostate cancer risk with insulin, glucose, and anthropometry in the Baltimore longitudinal study of aging. Urology. 2004;63(2):253–258
  79. Jonsson F, Wolk A, Pedersen NL, et al. Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish Twin Registry. Int J Cancer. 2003;106(4):594–599
  80. Howell MA. Factor analysis of international cancer mortality data and per capita food consumption. Br J Cancer. 1974;29:328–336
  81. Armstrong B, Doll R. Environmental factors and cancer incidence and mortality in different countries, with special references to dietary practices. Int J Cancer. 1975;15:617–631
  82. Kolonel LN, Hankin JH, Lee J, et al. Nutrient intakes in relation to cancer incidence in Hawaii. Br J Cancer. 1981;44:332–339
  83. Rose DP, Boyar AP, Wynder EL. International comparisons of mortality rates for cancer of the breast, ovary, prostate, and colon, and per capita food consumption. Cancer. 1986;58(11):2363–2371
  84. Giovannucci E, Rimm EB, Colditz GA, et al. A prospective study of dietary fat and risk of prostate cancer. J Natl Cancer Inst. 1993;85(19):1571–1579
  85. Dagnelie PC, Schuurman AG, Goldbohm RA, et al. Diet, anthropomometric measures and prostate cancer risk: a review of prospective cohort and intervention studies. BJU Int. 2004;93(8):1139–1150
  86. Whittemore AS, Kolonel LN, Wu AH, et al. Prostate cancer in relation to diet, physical activity, and body size in blacks, whites, and Asians in the United States and Canada. J Natl Cancer Inst. 1995;87(9):652–661
  87. Lee MM, Wang RT, Hsing AW, et al. Case-control study of diet and prostate cancer in China. Cancer Causes Control. 1998;9(6):545–552
  88. Sonoda T, Nagata Y, Mori M, et al. A case-control study of diet and prostate cancer in Japan: possible protective effect of traditional Japanese diet. Cancer Sci. 2004;95(3):238–242
  89. Augustsson K, Michaud DS, Rimm EB, et al. A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2003;12(1):64–67
  90. Norrish AE, Skeaff CM, Arribas GL, et al. Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. Br J Cancer. 1999;81(7):1238–1242
  91. Kolonel LN, Nomura AMY, Cooney RV. Dietary fat and prostate cancer: current status. J Natl Cancer Inst. 1999;91(5):414–428
  92. Lee MM, Gomez SL, Chang JS, et al. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev. 2003;12(7):665–668
  93. Jacobsen BK, Knutsen SF, Fraser GE. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). Cancer Causes Control. 1998;9(6):553–557
  94. Onozawa M, Fukuda K, Ohtani M, et al. Effects of soybean isoflavones on cell growth and apoptosis of the human prostatic cancer cell line LNCaP. Jpn J Clin Oncol. 1998;28(6):360–363
  95. Nagata C, Takatsuka N, Shimizu H, et al. Effect of soymilk consumption on serum estrogen and androgen concentrations in Japanese men. Cancer Epidemiol Biomarkers Prev. 2001;10(3):179–184
  96. Yi MA, Son HM, Lee JS, et al. Regulation of male sex hormone levels by soy isoflavones in rats. Nutr Cancer. 2002;42(2):206–210
  97. Yang G-Y, Liao J, Kim K, et al. Inhibition of growth and induction of apoptosis in human cancer cell lines by tea polyphenols. Carcinogenesis. 1998;19:611–616
  98. Hastak K, Gupta S, Ahmad N, et al. Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene. 2003;22(31):4851–4859
  99. Jian L, Xie LP, Lee AH, et al. Protective effect of green tea against prostate cancer: a case-control study in Southeast China. Int J Cancer. 2004;108(1):130–135
  100. Lycopene – a monograph. Alternative Med Rev 2003, 8(3), 336–342
  101. Stahl W, Sies H. Uptake of lycopene and its geometrical isomers is greater from heat-processed than from unprocessed tomato juice in humans. J Nutr. 1992;122:2161–2166
  102. Gann PH, Ma J, Giovannucci E, et al. Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. Cancer Res. 1999;59(6):1225–1230
  103. Binns CW, LJ LJ, Lee AH. The relationship between dietary carotenoids and prostate cancer risk in Southeast Chinese men. Asia Pac J Clin Nutr. 2004;13(Suppl.):S117
  104. Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: a meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev. 2004;13(3):340–345
  105. Willett WC, Polk BF, Morris JS, et al. Prediagnostic serum selenium and risk of cancer. Lancet. 1983;2(8342):130–134
  106. Hartman TJ, Albanes D, Pietinen P, et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene cancer prevention study. Cancer Epidemiol Biomarkers Prev. 1998;7(4):335–340
  107. Helzlsouer KJ, Huang HY, Alberg AJ, et al. Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst. 2000;92(24):2018–2023
  108. van den Brandt PA, Zeegers MP, Bode P, et al. Toenail selenium levels and the subsequent risk of prostate cancer: a prospective cohort study. Cancer Epidemiol Biomarkers Prev. 2003;12(9):866–871
  109. Li H, Stampfer MJ, Giovannucci EL, et al. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst. 2004;96(9):696–703
  110. Vogt TM, Ziegler RG, Graubard BI, et al. Serum selenium and risk of prostate cancer in US blacks and whites. Int J Cancer. 2003;103(5):664–670
  111. Nomura AM, Lee J, Stemmermann GN, et al. Serum selenium and subsequent risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2000;9(9):883–887
  112. Hartman TJ, Albanes D, Peitinen P, et al. The association between baseline vitamin E, selenium, and prostate cancer in the alpha-tocopherol, beta-carotene prevention study. Cancer Epidemiol Biomarkers Prev. 1998;7:335–340
  113. Chan JM, Stampfer MJ, Ma J, et al. Supplemental vitamin E intake and prostate cancer risk in a large cohort of men in United States. Cancer Epidemiol Biomarkers Prev. 1999;8:893–899
  114. Virtamo J, Pietinen P, Huttunen JK, et al. ATBC study group. Incidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a postintervention follow-up. JAMA. 2003;290(4):476–485
  115. Klein EA, Thompson IM, Lippman SM, et al. SELECT: the next prostate cancer prevention trial. Selenium and vitamin E cancer prevention trial. J Urol. 2001;166(4):1311–1315

PII: S0959-8049(05)00107-3

doi: 10.1016/j.ejca.2004.12.033

European Journal of Cancer
Volume 41, Issue 6 , Pages 834-845 , April 2005

Article Tools

* Image Usage & Resolution